Sphera Funds Management’s Neurocrine Biosciences NBIX Stock Holding History

Sphera Funds Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-37,000	Closed	-$2.87M	–	129
2017 Q4	$2.87M	Sell	37,000 -50,000	-57%	-$3.41M	0.34%	75
2017 Q3	$5.33M	Buy	87,000 +25,000	+40%	+$1.32M	0.76%	33
2017 Q2	$2.85M	Sell	62,000 -88,000	-59%	-$4.27M	0.48%	63
2017 Q1	$6.5M	Buy	+150,000	New	+$6.43M	1.27%	17
2016 Q2	–	Sell	-70,000	Closed	-$2.77M	–	105
2016 Q1	$2.77M	Buy	+70,000	New	+$2.78M	0.6%	32
2015 Q2	–	Sell	-75,000	Closed	-$2.98M	–	149
2015 Q1	$2.98M	Buy	75,000 +25,000	+50%	+$894K	0.31%	80
2014 Q4	$1.12M	Buy	+50,000	New	+$947K	0.19%	107

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sphera Funds Management's NBIX Position: Q1 2018 in Review

Sphera Funds Management sold out of Neurocrine Biosciences (NBIX) in Q1 2018, closing a stake of 37,000 shares — an estimated $2.87M sold.

Sphera Funds Management first reported a position in NBIX in Q4 2014 and held it in 7 quarters. The position peaked at $6.5M in Q1 2017. 267 funds tracked by Wall St. Rank hold NBIX as of Q1 2018.

Sphera Funds Management reported no remaining Neurocrine Biosciences position as of Q1 2018 after selling out during the quarter.
Sphera Funds Management sold 37,000 Neurocrine Biosciences shares in Q1 2018, an estimated $2.87M.
Sphera Funds Management first reported a position in Neurocrine Biosciences in Q4 2014 and held it in 7 quarters.
Sphera Funds Management's Neurocrine Biosciences position peaked at $6.5M in Q1 2017.
267 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2018.

Based on Sphera Funds Management's 13F filing for Q1 2018, filed 10 May 2018.